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Epithelial-mesenchymal transition (EMT) is a molecular
and cellular program in which epithelial cells lose their
well-differentiated phenotype and adopt mesenchymal
characteristics. This process occurs during the progres-
sion of cancer to metastatic disease, and is also asso-
ciated with recurrence as conventional therapies fail to
eliminate the minority of resistant tumor cells that have
undergone EMT. Brachyury is a transcription factor that
controls EMT during development, and we have shown
that brachyury is aberrantly overexpressed in various
human cancers where it promotes tumor cell EMT,
metastatic dissemination, and resistance to conventional
therapies. Further, we have recently reported that very
high expression of brachyury can protect against cas-
pase-dependent immune cell-mediated cytotoxicity.
In seeking to elucidate mechanisms of immunotherapy
resistance, we have discovered a novel association
between brachyury and mucin-1 (MUC1). MUC1 is over-
expressed in the majority of carcinomas, and it has been
shown to mediate oncogenic signaling, induce EMT,
increase stem cell characteristics, and confer resistance to
genotoxic agents. Here, we report a novel positive asso-
ciation between brachyury and MUC1 in both cancer cell
lines and patient tumor tissues, in which brachyury was
found to upregulate MUC1 expression at the level of
transcript stability. Targeting MUC1 by siRNA-based
gene silencing was found to abrogate the resistance of
brachyury-expressing tumor cells to killing by recombi-
nant tumor necrosis-related apoptosis-inducing ligand
(TRAIL) and to lysis by natural killer (NK) cells. These
studies confirm a protective role for MUC1 as a mediator
of immunotherapy-resistance in brachyury-expressing
tumor cells, and demonstrate that targeting MUC1
restores the susceptibility of mesenchymal tumor cells to
immune attack.
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